A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy
Tekijät: Bialas, Piotr; Kobayashi, Tamae; Hellsten, Rebecka; Krzyzanowska, Agnieszka; Persson, Margareta; Marginean, Felicia; Trudel, Dominique; Garraway, Isla P.; Trock, Bruce J.; Taimen, Pekka; Saad, Fred; Mirtti, Tuomas; Knudsen, Beatrice; De Marzo, Angelo M.; Bjartell, Anders
Kustantaja: Wiley
Julkaisuvuosi: 2025
Journal: Prostate
Tietokannassa oleva lehden nimi: The Prostate
Vuosikerta: 85
Numero: 3
Aloitussivu: 209
Lopetussivu: 323
ISSN: 0270-4137
eISSN: 1097-0045
DOI: https://doi.org/10.1002/pros.24820
Verkko-osoite: http://doi.org/10.1002/pros.24820
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/470933355
Background
The transcription factor Signal Transducer and Activator of Transcription 3 (STAT3) plays a role in carcinogenesis and is involved in processes, such as proliferation, differentiation, drug resistance and immunosuppression. STAT3 can be activated by phosphorylation of tyrosine at position 705 (pSTAT3Tyr705) or serine at 727 (pSTAT3Ser727). High expression levels of pSTAT3 are implicated in advanced stages of prostate cancer (PCa) and are known to interact with the androgen receptor signaling pathway. However, not much is known about how androgen deprivation therapy (ADT) in advanced disease affects pSTAT3 expression. The aim of this study was to determine the influence of ADT on pSTAT3 expression in PCa tissue.
Methods
The study cohort came from a PCa tissue microarray resource containing prostate specimens from patients before and post-initiation of ADT. Tissue samples from 111 patients were immunostained for pSTAT3Tyr705 and pSTAT3Ser727. H-score was used to evaluate the intensity and the percentage of pSTAT3 expression in malignant epithelial and stromal compartments. Univariate and multivariable Cox regression analyses were used to assess pSTAT3Tyr705 and pSTAT3Ser727 as biomarkers of oncological outcome in patients undergoing ADT.
Results
Post-ADT PCa samples demonstrated increased nuclear and cytoplasmic levels of pSTAT3Ser727 in the stroma compared to pre-ADT samples, whereas pSTAT3Tyr705 expression was increased significantly in both stromal and malignant epithelial compartments except for stromal cytoplasm. High cytoplasmic pSTAT3Ser727 in stromal compartments correlated with reduced overall survival, shorter time to castration-resistant PCa development, and decreased metastasis-free survival. An increase in nuclear and cytoplasmic pSTAT3Ser727 expression within the stromal compartment of post-ADT samples corresponded to a shorter time to CRPC development, which was not observed for pSTAT3Tyr705. Multivariable survival analysis using Cox's regression identified that high cytoplasmic pSTAT3Ser727 expression in the stroma of post-ADT samples and pT3 or pT4-stage were associated with worse overall survival and 5-year metastasis-free survival (MFS).
Conclusions
This study presents novel insights into the impact of ADT on the expression levels of pSTAT3Tyr705 and pSTAT3Ser727 in PCa. Cytoplasmic pSTAT3Ser727 status of cancer-associated stromal cells in post-ADT samples may serve as an independent prognostic marker for OS and 5-year MFS, identifying prostate cancer patients prone to developing resistance to ADT.
Ladattava julkaisu This is an electronic reprint of the original article. |
Julkaisussa olevat rahoitustiedot:
This work was supported by grants from the Swedish Cancer Society (Cancerfonden, 21 1629 Pj 01 H), and the Swedish Scientific Council (Vetenskapsrådet, 2020-02017), ALF (Lund University), the Skåne University Hospital Research Foundations, Kungliga Fysiografiska Sällskapet i Lund (43193). B.J. Trock, P. Taimen, F. Saad, T. Mirtti, B.S. Knudsen, and A.M. De Marzo were funded by Movember. B.J. Trock and A.M. De Marzo from JHU were supported by U.S. NIH/NCI SPORE in Prostate Cancer: P50CA58236, the U.S. Department of Defense Prostate Cancer Research Program (PCRP): W81XWH-18-2-0015 to A.M. De Marzo. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Oncology Tissue Services Laboratory supported by U.S. NIH/NCI P30 CA006973 (to B.J. Trock and A.M. De Marzo). CRCHUM was supported by the FRQS (to F. Saad, and D. Trudel) and their Biobanking at the CRCHUM was done in collaboration with the Réseau de recherche sur le cancer supported by the Fonds de Recherche Québec - Santé (FRQ-S) affiliated to the Canadian Tissue Repository Network (CTRNet).